secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-04-19T23:59:59+00:00
Accession:  0000886163-24-000013
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand adopts amended bylaws for universal proxy rules and DGCL updates
-----------------------------------------------------------------------

- Board approved Fifth Amended and Restated Bylaws on April 17, 2024.
- Updates include requirements for stockholder nominations under Rule 14a-19 (universal proxy).
- Clarifies broker non-votes have no effect; abstentions count as votes against.
- Revisions reflect changes to Delaware General Corporation Law on electronic notices and stockholder lists.
- Also makes conforming changes to stockholder proposal and nomination procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/0000886163-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/lgnd-20240417.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer